In the pull-ahead, fall-back race for a drug against hereditary angioedema (HAE), Dyax Corp. regained some lost ground with news that Icatibant - the synthetic peptidomimetic from would-be competitors Kos Pharmaceuticals Inc. and Jerini AG - missed its primary endpoints in one Phase III trial, but hit the primary endpoint in another. (BioWorld Today) Read More
